Fas, Fas-Associated Death Domain-Like Interleukin 1β-Converting Enzyme-Like Inhibitory Protein, and Apoptotic Features of Elderly Acute Myeloid Leukemia Based on Response to Induction Chemotherapy
- 31 Downloads
A study was performed to examine the clinical outcome of triple-combination induction chemotherapy in 26 elderly Korean acute myeloid leukemia (AML) patients and to investigate apoptotic responses during and after treatment to determine whether the responses can be used as prognostic markers. Patients who had Western blot or polymerase chain reaction analysis findings of higher expression levels of Fas-associated death domain-like interleukin 1β-converting enzyme-like inhibitory protein (FLIP) on day 7 after chemotherapy were more likely to have complete remission, but there was less or no correlation with Fas or a proapoptosis/apoptosis reaction. Expression of FLIP molecules may be, at least in part, an early prognostic indicator in the treatment of elderly AML patients.
Key wordsInduction chemotherapy Elderly AML patients Apoptotic responses FLIP molecule
Unable to display preview. Download preview PDF.
- 1.Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkable distinct response to standard chemotherapy-a Southwest Oncology Group study.Blood. 1997;89:3323–3329.PubMedGoogle Scholar
- 5.Hamblin TJ. The treatment of acute myeloid leukemia preceded by the myelodysplastic syndrome.Leukemia Res. 1992;16:4101–4108.Google Scholar
- 11.Buchner T, Hiddemann W, Schaefer UW, et al. Combined effect of very early intensification and prolonged post-remission chemotherapy in patients with AML.Leukemia. 1992;6(suppl 4):68–70.Google Scholar
- 23.Lowenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone vs daunorubicin in induction-consolidation chemotherapy-the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukaemia in the elderly: final report. European Organization of the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.J Clin Oncol. 1998;16:872–881.PubMedGoogle Scholar
- 25.Lowenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission induction chemotherapy in elderly patients of 65+ years with acute myeloid leukaemia: a randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukaemia Group.J Clin Oncol. 1989;7:1268–1274.PubMedGoogle Scholar
- 26.Foon KA, Zighelboim J, Yale C, Gale RP. Intensive chemotherapy is the treatment of choice for elderly patients with acute myelogenous leukaemia.Blood. 1981;3:467–470.Google Scholar